Table of Content

1 Markets
1.1 Industry Outlook
1.1.1 Market Overview and Ecosystem
1.1.2 Key Trends
1.1.2.1 Biomanufacturing 4.0
1.1.2.2 Growing Single-Use Technology Market Penetration
1.1.2.3 Shift from Open Processing to Closed Processing for Cell and Gene Therapy Biomanufacturing
1.1.2.4 Leveraging Various Key Strategies to Diversify the Product Portfolio
1.1.3 Opportunity Assessment
1.1.4 Regulatory Framework
1.1.5 Product Benchmarking
1.1.5.1 Product Benchmarking (by Product Type)
1.1.5.2 Comparative Analysis (by Equipment)
1.1.6 Patent Analysis
1.1.6.1 Patent Analysis (by Year)
1.1.6.2 Patent Analysis (by Country)
1.1.6.3 Awaited Technologies
1.1.7 Business Model Analysis
1.1.8 Pipeline Products
1.1.9 Technology Adoption Matrix
1.1.10 Funding Scenario
1.1.11 Key Success Factors
1.2 Impact of COVID-19 on the Cell and Gene Therapy Biomanufacturing Market
1.2.1 Recommendations to Manufacturers
1.3 Impact of Russo-Ukrainian War on Cell and Gene Therapy Biomanufacturing Market

2 Asia-Pacific
2.1 Asia-Pacific
2.1.1 Key Findings and Opportunity Assessment
2.1.2 Market Dynamics
2.1.2.1 Impact Analysis
2.1.3 Sizing and Forecast Analysis
2.1.3.1 Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type)
2.1.3.2 Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User)
2.1.3.3 Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Country)
2.1.3.3.1 China
2.1.3.3.1.1 China Cell and Gene Therapy Biomanufacturing Market (by Product Type)
2.1.3.3.1.2 China Cell and Gene Therapy Biomanufacturing Market (by End User)
2.1.3.3.2 Japan
2.1.3.3.2.1 Japan Cell and Gene Therapy Biomanufacturing Market (by Product Type)
2.1.3.3.2.2 Japan Cell and Gene Therapy Biomanufacturing Market (by End User)
2.1.3.3.3 India
2.1.3.3.3.1 India Cell and Gene Therapy Biomanufacturing Market (by Product Type)
2.1.3.3.3.2 India Cell and Gene Therapy Biomanufacturing Market (by End User)
2.1.3.3.4 South Korea
2.1.3.3.4.1 South Korea Cell and Gene Therapy Biomanufacturing Market (by Product Type)
2.1.3.3.4.2 South Korea Cell and Gene Therapy Biomanufacturing Market (by End User)
2.1.3.3.5 Australia/New Zealand
2.1.3.3.5.1 Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market (by Product Type)
2.1.3.3.5.2 Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market (by End User)
2.1.3.3.6 Rest-of-Asia-Pacific
2.1.3.3.6.1 Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type)
2.1.3.3.6.2 Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User)

3 Markets - Competitive Benchmarking and Company Profiles
3.1 Competitive Benchmarking
3.1.1 Competitive Landscape
3.1.1.1 Segmental Growth Share Matrix
3.1.1.1.1 Growth Share Analysis (by Product Type)
3.1.1.1.2 Growth Share Analysis (by Application)
3.1.1.2 Competitive Index (Unmet Needs and Innovations)
3.1.1.3 Company Position Analysis
3.1.1.4 Key Strategies and Developments
3.1.1.4.1 Funding Activities
3.1.1.4.2 New Offerings
3.1.1.4.3 Mergers and Acquisitions
3.1.1.4.4 Partnerships, Alliances, and Business Expansions
3.1.1.4.5 Key Development Analysis
3.2 Company Share Analysis
3.3 Company Profiles
3.3.1 WuXi AppTec
3.3.1.1 Company Overview
3.3.1.2 Role of WuXi AppTec in the Cell and Gene Therapy Biomanufacturing Market
3.3.1.3 Major Product: Key Specifications
3.3.1.4 Customers and Competitions/Opportunities
3.3.1.4.1 Key Competitors
3.3.1.5 Analyst Perspective
List of Figures
Figure 1: Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 2: Cell and Gene Therapy Biomanufacturing Market: Drivers, Restraints, and Opportunities
Figure 3: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Impact Analysis
Figure 4: Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion, 2021-2031
Figure 5: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Region), $Billion, 2021 and 2031
Figure 6: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Share of Key Developments and Strategies (by Category), January 2020-January 2023
Figure 7: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market Segmentation
Figure 8: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market: Research Methodology
Figure 9: Primary Research Methodology
Figure 10: Bottom-Up Approach (Segment-Wise Analysis)
Figure 11: Top-Down Approach (Segment-Wise Analysis)
Figure 12: Market Overview and Ecosystem
Figure 13: Insights on Strategies Adopted by Major Players, January 2020-January 2023
Figure 14: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Key Trends, Market Shift, 2022-2031
Figure 15: TcBuster vs. Viral Gene Engineering Technology, Comparative Analysis
Figure 16: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Patent Analysis (by Year), January 2020-December 2022
Figure 17: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Patent Analysis (by Country), January 2020-December 2022
Figure 18: Anticipated Regulatory Milestones in 2023
Figure 19: Anticipated Regulatory Approval, U.S. and EU, 2023
Figure 20: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Technology Adoption Matrix
Figure 21: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Key Success Factors
Figure 22: Impact of COVID-19 on CGT Developmental Activities
Figure 23: Progress in Cell and Gene Therapy (CGT) Regulation during COVID-19
Figure 24: Ways to Increase Supply Chain and Manufacturing
Figure 25: Impact on Biopharmaceutical Industries
Figure 26: Cell and Gene Therapy Biomanufacturing Market Share (by Region)
Figure 27: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market Incremental Revenue Opportunity (by Country), $Billion, 2021-2031
Figure 28: Ongoing Clinical Trials, Asia-Pacific (by Country)
Figure 29: Incidence of Hematologic Malignancies, Asia, 2020 vs. 2040
Figure 30: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 31: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion, 2021-2031
Figure 32: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion, 2021-2031
Figure 33: China Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 34: China Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 35: China Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 36: Japan Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 37: Japan Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 38: Japan Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 39: Incidence of Leukemia, Multiple Myeloma and Immunoproliferative Diseases, and Non-Hodgkin’s Lymphoma, India, 2020 vs. 2040
Figure 40: India Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 41: India Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 42: India Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 43: Incidence of Leukemia, Multiple Myeloma and Immunoproliferative Diseases, and Non-Hodgkin’s Lymphoma, South Korea, 2020 vs. 2040
Figure 44: South Korea Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 45: South Korea Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 46: South Korea Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 47: Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 48: New Zealand Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 49: Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 50: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 51: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 52: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 53: Growth Share Analysis for Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type), 2021-2031
Figure 54: Growth Share Analysis for Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Application), 2021-2031
Figure 55: Competitive Index, Unmet Needs, Solutions, and Impacts
Figure 56: Company Position Analysis
Figure 57: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Total Number of Key Developments, January 2020-January 2023
Figure 58: Funding Activities, January 2020-January 2023
Figure 59: New Offerings, January 2020-September 2023
Figure 60: Mergers and Acquisitions, January 2020-January 2023
Figure 61: Partnerships, Alliances, and Business Expansion Activities, January 2020-January 2023
Figure 62: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Company Share Analysis, % Share, 2021
Figure 63: WuXi AppTec: Product Portfolio
List of Tables
Table 1: Key Questions Answered in the Report
Table 2: Single-Use and Stainless-Steel Facilities, Comparative Analysis
Table 3: Asia-Pacific Regulatory Scenario: Cell and Gene Therapy Biomanufacturing Market
Table 4: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type), Product Benchmarking
Table 5: Comparative Analysis of Various Bioreactors Offered by Key Players
Table 6: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Awaited Technologies
Table 7: Business Models, Key Features
Table 8: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market Dynamics, Impact Analysis
Table 9: Approved Cell and Gene Therapies, Japan
Table 10: Ongoing Industry Sponsored Cell and Gene Therapy Clinical Trials
Table 11: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Key Development Analysis, January 2020-January 2023